Esteban Jódar Gimeno

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide

Vivian Fonseca, Matthew Capehorn, Satish K. Garg et al. · The Journal of Clinical Endocrinology & Metabolism · 2019 · 62 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Prevalence of osteoporosis, vertebral fractures and hypovitaminosis D in postmenopausal women living in a rural environment

María-Jesús Gómez-de-Tejada Romero, María-del-Carmen Navarro Rodríguez, José-Manuel Quesada Gómez et al. · Maturitas · 2014 · 30 citations

Medicine, Endocrinology, Orthopedic Surgery +17